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As expected with all antithrombotic agents, there is a risk of bleeding complications in patients receiving
direct oral anticoagulants (DOACs) because of the DOAC itself, acute trauma, invasive procedures, or
underlying comorbidities. For many bleeding events, a prudent course of action will be to withdraw the
DOAC, then “wait and support” the patient, with the expectation that the bleeding event should resolve with
time. Likewise, DOAC therapy may be interrupted ahead of a planned procedure, the stopping time being
dependent on the agent involved and the patient’s renal function. However, urgent reversal of anti-
coagulation is required in patients with serious or life-threatening bleeding or in those requiring urgent
surgery or procedures. Novel speciﬁc reversal agents, either under development or recently approved, will
need to be incorporated into local anticoagulation reversal protocols. For dabigatran-treated patients,
idarucizumab recently has been approved for clinical use in cases of life-threatening or uncontrolled
bleeding or when patients require emergency surgery or urgent procedures, both associated with a high risk
of bleeding. As clinical experience with individual speciﬁc reversal agents grows, their roles in managing
major bleeding events in DOACetreated patients will become better deﬁned. Future research, as well as
ongoing use of idarucizumab, should help establish when it is appropriate to re-dose with idarucizumab, co-
administer with prothrombin complex concentrates, or re-initiate DOAC after idarucizumab use. Ongoing
trials should help identify the appropriate doses and expected durations of effect for andexanet alfa and
ciraparantag, which are likely to vary depending on the individual oral anticoagulants.
 2016 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).  The American Journal of Medicine (2016) 129, S89-S96
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thromboembolic events in patients with nonvalvular atrial
ﬁbrillation. Historically, the vitamin K antagonist, warfarin,
was the oral anticoagulant of choice, generating decades of
experience and corresponding data.1 More recently, the
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factors such as acute trauma or invasive procedures, or by
underlying comorbidities. Although bleeding-related out-
comes in clinical trials of DOACs in patients with atrial
ﬁbrillation have been favorable,4-7 the lack of a reversal
agent often has been considered as a disadvantage for
DOACs.3,8 This has prompted the development of the spe-
ciﬁc reversal agents (reviewed in articles by Reilly et al,
Pollack, and Milling and Kaatz in this special issue).9-11
Idarucizumab (Boehringer Ingelheim International GmbH,
Ingelheim, Germany) is a humanized monoclonal antibody
fragment that speciﬁcally binds to dabigatran and is
approved by the U.S. Food and Drug Administration and the
European Medicines Agency for use in dabigatran-treated
patients who require reversal of the anticoagulant effects
of dabigatran (ie, if there is life-threatening or uncontrolled
bleeding, or for emergency surgery/urgent procedures).12
There are a further 2 speciﬁc reversal agents in develop-
ment: andexanet alfa (r-Antidote, Portola Pharmaceuticals,
Inc, South San Francisco, Calif), a factor Xa decoy thatTable 1 European Heart Rhythm Association Guidelines for Pract
Anticoagulated with a DOAC
Direct Thrombin Inhibitors (Dabigatran
Non-life-threatening bleeding Inquire last intake and dosing regimen
Estimate normalization of hemostasis:
Normal renal function: 12-24 h
CrCl 50-80 mL/min: 24-36 h
CrCl 30-50 mL/min: 36-48 h
CrCl <30 mL/min: 48 h
Maintain diuresis
Local hemostatic measures:
Fluid replacement (colloids if neede
RBC substitution if necessary
Platelet substitution (in case of thro
60  109/L or thrombopathy)
Fresh-frozen plasma as plasma expan
reversal agent)
Tranexamic acid can be considered a
Consider dialysis (preliminary evidence
dabigatran can be removed after 4 h
Charcoal hemoperfusion can be consid
preclinical data).
Life-threatening bleeding All of the above
Idarucizumab 5 g IV
PCC 50 U/kg (with additional 25 U/kg
needed) (but no clinical data)
Activated PCC (50 U/kg; max 200 U/kg
data about additional beneﬁt over P
considered before PCC if available.
Activated FVII (rFVIIa; 90 mg/kg), no
additional beneﬁt and expensive (on
evidence)
CrCl ¼ creatinine clearance; FVII ¼ factor VII; IV ¼ intravenously;
rFVIIa ¼ recombinant factor VIIa.
Adapted from Heidbuchel et al.15binds to direct and indirect factor Xa inhibitors; and cir-
aparantag (Perosphere Inc, Danbury, Conn), a potential
reversal agent for both direct and indirect factor Xa in-
hibitors, as well as factor IIa inhibitors.13,14
The objective of this review is to provide practical
guidance that can be used when incorporating these
DOACespeciﬁc reversal agents into existing guidelines and
protocols for the management of serious bleeding events or
in patients undergoing urgent surgery while receiving
DOACs. The review also discusses how the individual
reversal agents may be used, as well as any unresolved is-
sues that might be addressed by ongoing and future trials.CURRENT GUIDELINES AND STRATEGIES FOR
DOAC REVERSAL
The European Heart Rhythm Association (EHRA) has
provided guidance for clinicians managing bleeding events
(Table 1) and surgical procedures in DOAC-treated
patients with nonvalvular atrial ﬁbrillation, as have otherical Measures to Help Control Bleeding in Patients Who Are
)
Factor Xa Inhibitors (Apixaban, Edoxaban,
and Rivaroxaban)
d)
mbocytopenia
der (not as
s an adjuvant.
: w65% of
).
ered (based on
Inquire last intake and dosing regimen
Normalization of hemostasis: 12-24 h
Local hemostatic measures:
Fluid replacement (colloids if needed)
RBC substitution if necessary
Platelet substitution (in case of
thrombocytopenia 60  109/L or
thrombopathy)
Fresh-frozen plasma as plasma expander
(not as reversal agent)
Tranexamic acid can be considered as an
adjuvant.
Desmopressin can be considered in special
cases (coagulopathy or thrombopathy).
if clinically
/d), no strong
CC. Can be
data about
ly animal
All of the above
PCC 50 U/kg (with additional 25 U/kg if
clinically needed) (healthy volunteer data)
Activated PCC (50 U/kg; max 200 U/kg/d),
no strong data about additional beneﬁt
over PCC. Can be considered before PCC if
available.
Activated FVII (rFVIIa; 90 mg/kg), no data
about additional beneﬁt and expensive
(only animal evidence)
PCC ¼ prothrombin complex concentrate; RBC ¼ red blood cells;
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Society of Critical Care Medicine have devised guidelines
for DOAC reversal in patients with intracranial
hemorrhage.19Bleeding Events and Hemostasis
As a consequence of the short half-life and predictable
pharmacokinetics of the DOACs, most bleeding events can
be resolved simply by waiting long enough (12-24 hours)
for the DOAC plasma levels to decline to subtherapeutic
concentrations while providing supportive measures to the
patient.15,20 Key parameters that will guide the selection of
this “wait and support” approach are the timing of the last
dose and qualitative estimates from routine laboratory
coagulation assays to establish the general range of the
DOAC-induced anticoagulation effect. In addition, factors
inﬂuencing plasma concentrations should be taken into
consideration, such as drugedrug interactions and the pa-
tient’s renal function. In patients receiving dabigatran, theFigure Suggested algorithm for the management of da
episode or who require urgent surgery/invasive procedur
(each containing 2.5 g) intravenously. In rare cases whe
course of idarucizumab, and bleeding continues in the p
considered. aPTT ¼ activated partial thromboplastin tim
time. Reproduced with permission from: Eikelboom JW,
antidote for reversal of dabigatran. Circulation. 2015;13time to drug elimination is strongly inﬂuenced by renal
function. Dialysis may be considered to increase dabigatran
clearance, although there is limited clinical experience to
support the use of dialysis in this setting.15,21
Patients with life-threatening or uncontrolled bleeding,
however, require more immediate reversal of the anticoag-
ulant effects of DOACs. Prothrombin complex concentrates
and activated prothrombin complex concentrates have been
used for reversal of DOAC anticoagulation, although their
efﬁcacy has not been ﬁrmly established in prospective,
randomized trials15,22 (see review by Eikelboom and Merli23
in this special issue). The potential anticoagulant reversal
beneﬁts of prothrombin complex concentrates and activated
prothrombin complex concentrates also need to be balanced
against their potential prothrombotic effects.15,24,25 Both the
updated EHRA practical guide and the Neurocritical Care
Society/Society of Critical Care Medicine intracranial
hemorrhage guidelines recommend administering the
recently approved reversal agent, idarucizumab, in patients
receiving dabigatran.15,19 A proposed algorithm for decidingbigatran-treated patients who experience a bleeding
es. *Administer two 50-mL vials of idarucizumab
n dabigatran-related anticoagulation persists after a
atient, a second 5 g dose of idarucizumab may be
e; dTT ¼ diluted thrombin time; TT ¼ thrombin
Quinlan DJ, van Ryn J, Weitz JI. Idarucizumab: the
2:2412-2422.26
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Figure. In the absence of a currently approved speciﬁc
reversal agent for factor Xa inhibitors, these guidelines
recommend prothrombin complex concentrates or
activated prothrombin complex concentrates in patients
receiving apixaban, edoxaban, or rivaroxaban.Patients Undergoing Planned or Urgent Surgery
The EHRA practical guide also contains guidance on when
to stop DOAC therapy in patients undergoing a planned
surgical procedure that carries a bleeding risk. The timing of
the withdrawal of the DOAC is dependent on the particular
agent, patient factors (eg, kidney function, age, history of
bleeding, and concomitant medication), and the degree of
bleeding risk associated with individual procedures. Dabi-
gatran therapy should be stopped at least 24 to 48 hours
ahead of low-risk procedures, depending on renal function,
and at least 48 to 96 hours ahead of high-risk procedures.
The factor Xa inhibitors should be stopped at least 24 to 36
hours before low-risk procedures and at least 48 hours
before high-risk procedures.12 Common coagulation tests
(eg, activated partial thromboplastin time for dabigatran)
may be helpful in providing a qualitative evaluation of the
waning anticoagulant effects, as may speciﬁc coagulation
tests (diluted thrombin time for dabigatran or chromogenic
anti-factor Xa assays for factor Xa inhibitors) that are not yet
approved in the United States.15
These stopping times may not always be feasible for more
urgent procedures, and in these cases, reversal of anti-
coagulation is required. As is the case in patients with
life-threatening bleeding, prospective data on the use of pro-
thrombin complex concentrates in the preoperative setting are
lacking.15 Patients receiving dabigatran who require emer-
gency surgery or urgent proceduresmay receive idarucizumab
(administered as 2 consecutive intravenous infusions of 2.5 g
in 50 mL apiece) for the reversal of dabigatran (Figure).12 A
published interim analysis of the phase 3, cohort study
Reversal Effects of Idarucizumab on Active Dabigatran
(RE-VERSE AD) included 39 patients receiving dabigatran
who required a surgery or procedure that could not be delayed
for at least 8 hours and required normal hemostasis.27,28 In
these patients, idarucizumab reversed the anticoagulant ef-
fects of dabigatran (as assessed by diluted thrombin time or
ecarin clotting time) in 93% and 88% of patients, respectively.
Of note, idarucizumab obviated the need for surgery in 1
patient, and 2 patients were too unstable for surgery. In the 36
patients who subsequently had a procedure, 33 were consid-
ered to have normal intraoperative hemostasis by the
investigator.27KEY CONSIDERATIONS FOR SPECIFIC REVERSAL
AGENTS
With the increasing availability of the speciﬁc reversal in-
hibitors, clinicians will be required to incorporate these
agents into their institutional guidelines/protocols for theurgent reversal of DOACs. This will raise a number of
considerations, which are discussed in the following sec-
tions. Because conditions can vary between institutions,
each organization may need to adapt existing guidelines to
their particular situation as they consider the key factors that
inﬂuence patient outcomes. An example of a template local
guidance document can be found in Table 2, which is
provided as a starting point for the development of more
individualized local protocols.Appropriate Patient Selection
As discussed earlier, the use of speciﬁc reversal agents
should be reserved for life-threatening bleeding or in
patients in whom an urgent invasive procedure is required.
The approved uses for these agents are likely to differ on
the basis of the patient populations studied in phase 3 trials.
The idarucizumab phase 3 trial (Reversal Effects of Idar-
ucizumab on Active Dabigatran [RE-VERSE AD]) included
adult patients with overt, uncontrollable, or life-threatening
bleeding (group A) or who required surgery or other inva-
sive procedures that could not be delayed for at least 8 hours
(group B).27,28 Patients were selected on the basis of clinical
judgment that immediate reversal was required and included
those with acute trauma, as well as those who were expected
to die within 3 days or require surgery within 24 hours.27
The approved indication for idarucizumab reﬂects this trial
population.12
In contrast, the ongoing phase 3 andexanet alfa trial
(Andexanet Alfa a Novel Antidote to the Anticoagulant
Effects of FXa Inhibitors [ANNEXA]-4; NCT02329327)
includes patients with an acute major bleeding episode
requiring urgent reversal of apixaban, rivaroxaban, edox-
aban, or enoxaparin (administered in the past 18 hours).29
Patients expected to undergo surgery (excluding minimally
invasive procedures) in <12 hours are excluded, as are
patients with an expected survival of <1 month. The se-
lection of patients also is based on a set of predeﬁned
criteria: acute bleeding that is potentially life-threatening, in
a critical area or organ, or associated or expected to be
associated with decreases in hemoglobin levels of 2 g/dL
or current or expected hemoglobin levels of 8 g/dL. Thus,
these criteria are similar to the current International Society
for Thrombosis and Haemostasis guidelines for nonsurgical
patients, although patients who have received blood prod-
ucts (including whole blood and prothrombin complex
concentrates) in the past 7 days are excluded.30 When
considering the magnitude of bleeding that may require
urgent reversal, the variability in major bleeding deﬁnitions
used in DOAC trials should be taken into account, as should
the variability in deﬁnitions of effective periprocedural he-
mostasis, which are used to determine the effectiveness of
management strategies.4-7,31
The differing mode of actions or drug targets of the in-
dividual agents (Table 3) will need to be taken into
consideration when selecting the appropriate agent.
Idarucizumab is speciﬁc to and only effective against
Table 2 Considerations Regarding Potential Use of Idarucizumab: Prototypical Table to Guide Decision-making
Indications
Life-Threatening or Uncontrolled
Bleeding
Emergency Surgery or Invasive
Procedures Moderate to Mild Bleeding
Criteria Life-threatening bleeding leading to
hemodynamic compromise or
threatening a vital organ (eg, CNS or
spinal cord, intraocular,
intrapulmonary, retroperitoneal, or
intramuscular with compartment
syndrome)
Unresponsive to conventional
measures
Potentially leading to disability
Emergency surgery or urgent
procedures that cannot be
delayed for at least 8 h and
that require immediate
hemostasis
Nonelife-threatening bleeding
that does not involve a vital
organ or in patients in whom
surgery or invasive procedures
can be delayed*
*Idarucizumab is NOT indicated
for cases of mild or moderate
bleeding.
Baseline laboratory tests
to assess anticoagulation
Need to order aPTT, ECT, or dTT in all patients when possible (depending on local availability of individual
assays):
Coagulation assay times that may indicate signiﬁcant elevation of coagulation parameters (results need to be
considered in light of local assay standards):
aPTT (median baseline PTT w50 sec)†21
ECT (median baseline ECT w75 sec)†27
dTT (median baseline dTT w45 sec)†27
Dabigatran ingestion
conﬁrmed?
Known timing/ingestion of dabigatran (prescribed anticoagulant,
standard dosage, known last dose?)
Potential dabigatran overdose (accidental, deliberate?)
Expected minimum timing for
elimination of clinically relevant
dabigatran concentrations:
CrCl 50 mL/min: 24 h
CrCl <50 mL/min: 48 h
Idarucizumab Consider administering idarucizumab immediately Idarucizumab is not
recommended for cases of
moderate to mild bleeding.
Dosing Intravenous administration of idarucizumab; 5 g total dose administered as
2 consecutive infusions or bolus injections of 2.5 g/50 mL each
Not applicable
Monitoring Signs and symptoms of bleeding or thrombotic events
Repeat aPTT, ECT, or dTT at 4 h and at 12-24 h postadministration
(as per local protocols)
Local resources Names and contact information of local experts, ofﬁces, and laboratories
that are available to guide patient selection and treatment choices
aPTT ¼ activated partial thromboplastin time; CNS ¼ central nervous system; CrCl ¼ creatinine clearance; dTT ¼ dilute thrombin time; ECT ¼ ecarin
clotting time; PTT ¼ partial thromboplastin time.
†Rounded median baseline values for each assay for patients taking dabigatran, as per listed citation. Values are provided for general guidance only;
need to consider performance of each assay under local or central laboratory conditions.
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oped to target the currently approved factor Xa inhibitors8,13
(and not dabigatran), and ciraparantag has been designed as
a “universal” inhibitor for DOACs and heparins.33-35,37
Therefore, the decision regarding which agent to use will
depend on which particular DOAC is prescribed. Patients
receiving speciﬁc reversal agents will need to receive
additional supportive care to control bleeding because the
reversal agents have been designed to reverse the antico-
agulant effect of DOACs rather than to control bleeding.Dosing and Administration
The 3 speciﬁc reversal agents are all administered intrave-
nously, with andexanet alfa requiring an infusion pump.
The recommended dose of idarucizumab is 5 g, which is
supplied in 2 separate vials (2.5 g/50 mL idarucizumab pervial) that are ready for administration by sequential bolus
injections or continuous intravenous infusion.12 The vials
need to be stored at a temperature range of 36F to 46F,
without freezing. Likewise, andexanet alfa is a recombinant
protein product that may need to be refrigerated and is ex-
pected to be administered at different doses according to the
particular factor Xa inhibitor in question. In light of these
recommendations, each institution will need to deﬁne its
“best option” storage location on the basis of internal in-
ventory control procedures and the relative ease-of-access in
emergency situations. Ciraparantag is stable at room tem-
perature, and thus, has the potential for out-of-hospital use.
In the RE-VERSE AD trial, idarucizumab demonstrated
immediate neutralization of dabigatran’s anticoagulant ac-
tivity.27 However, increases in unbound dabigatran con-
centration, which were accompanied by prolonged diluted
thrombin time and ecarin clotting time values, occurred in
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S94 The American Journal of Medicine, Vol 129, No 11A, November 2016some patients at 12 or 24 hours. This may be attributed to
the redistribution of dabigatran from the tissues back into
the plasma27 and highlights the need for an approved and
accessible assay for dabigatran, such as diluted thrombin
time or activated partial thromboplastin time. Administra-
tion of an additional 5-g dose of idarucizumab may be
considered in patients who have reappearance of clinically
relevant bleeding together with an elevated coagulation
parameter after administration of idarucizumab.12,41 Like-
wise, readministration of idarucizumab may be considered
in patients who require a second emergency procedure and
have elevated coagulation parameters. However, the safety
and effectiveness of repeat treatment with idarucizumab
have yet to be established.
Findings from phase 2 trials suggest that the dose of
andexanet alfa will vary depending on the anticoagulant
agent (see review by Milling and Kaatz in this special
issue).11 Doses of andexanet alfa used in the ANNEXA-A
and ANNEXA-R trials resulted in reversal of the anticoag-
ulant activity of apixaban or rivaroxaban in older healthy
participants within minutes after administration and for the
duration of the infusion.32 However, the appropriate dose of
andexanet alfa for apixaban or rivaroxaban in patients with
bleeding complications has yet to be deﬁned and may vary
depending on the time since the last anticoagulant dose, the
total body load of the anticoagulant agent, and the under-
lying renal function. Guidance will be required regarding
the optimal duration of the infusion, especially because a
readily available laboratory test to quantify levels of factor
Xa anticoagulation is currently lacking in the United States.
In addition, andexanet alfa doses and durations of therapy to
reverse the effects of low-molecular-weight heparins or
fondaparinux will need to be deﬁned, as will the appropriate
doses of ciraparantag to reverse the effects of the different
anticoagulants in clinical use.Coadministration with Nonspeciﬁc Hemostatic
Agents
As speciﬁc reversal agents continue to be approved for the
reversal of DOACs (factor II or factor Xa inhibitors), the
role, if any, that the currently available coagulation factors
or concentrates play in the management of pathologic
bleeding events can be expected to evolve.15,20,42 However,
there is limited clinical experience with the use of coagu-
lation concentrates and DOAC-speciﬁc reversal agents.
Patients with bleeding in the RE-VERSE AD trial were
permitted to receive supportive care, including prothrombin
complex concentrates and other blood products, during the
trial.28 Consequently, of the ﬁrst 90 patients, 4 received
activated prothrombin complex concentrates and 23
received fresh-frozen plasma.27 However, outcomes data
for these patients have not been reported. Furthermore,
blood products, including prothrombin complex concen-
trates, are not permitted in the ongoing major bleeding
andexanet alfa ANNEXA-4 trial within 7 days of
screening.29
Huisman and Fanikos Idarucizumab and Factor Xa Reversal Agents S95Re-Initiation of Anticoagulant Therapy
Clinicians also will need to decide when anticoagulation
should be reestablished after use of a speciﬁc reversal agent.
This will be dependent on the patient’s individual risk of
bleeding versus thromboembolism, but will also need to take
into account the reversal agent used. In healthy volunteers,
dabigatran anticoagulation could be reestablished within 24
hours of idarucizumab use.41 In the RE-VERSE AD trial,
most patients re-initiated anticoagulant therapy after
reversal, with the restart time varying: a median time of 4.1
days in patients with life-threatening bleeding versus 1.4
days in patients requiring urgent surgery.43 Although the
half-lives of dabigatran and idarucizumab are prolonged
in patients with renal impairment, the adjustment of timing
of re-initiation of dabigatran is not necessary.12,21 Data
are required to identify when anticoagulation may be
re-established after andexanet alfa or ciraparantag use,
particularly if patients require an emergent procedure with
extracorporeal life support and immediate heparinization.Safety
No safety concerns for idarucizumab were highlighted in the
RE-VERSE AD trial; the 18 deaths that were reported were
due to the index event or underlying condition, and the 5
thrombotic events (including 1 occurring within 72 hours of
idarucizumab administration) were in patients who had not
re-initiated anticoagulant therapy.27 This is in line with
preclinical and phase 1 trials in which idarucizumab showed
no prothrombotic effects (see the review by Reilly, et al in
this special issue).9 In addition, it should be noted that there
is a risk of serious adverse events with idarucizumab use in
patients with hereditary fructose intolerance resulting from
the sorbitol excipient.12
The safety of andexanet alfa and ciraparantag has yet to
be established in patients with bleeding complications.
Although andexanet alfa has demonstrated no procoagulant
activity in ex vivo clotting assays,13 transient increases in
the levels of D-dimer and prothrombin 1 and 2 were re-
ported in the ANNEXA-A and ANNEXA-R trials.32 How-
ever, this did not result in increases in thrombin generation
or thrombotic events in these healthy volunteers. Even so,
safety data from patients with major bleeding will be
required to exclude a potential prothrombotic effect with
andexanet alfa use.
As with all proteins, there is a potential for immunoge-
nicity with both idarucizumab and andexanet alfa. However,
preliminary data from trials in healthy volunteers suggest
that this may not be a concern for idarucizumab because it
has not been associated with the formation of new persistent
antibodies, and there were no adverse events suggestive of
immunogenic reactions.39 Likewise, in the ANNEXA-A and
ANNEXA-R trials, antibodies to factor X or factor Xa, as
well as neutralizing antibodies against andexanet alfa, were
not detected.32 However, further research will be required
to assess the immunogenicity of idarucizumab or
andexanet alfa in treated patients.CONCLUSIONS
Considerations of speciﬁc anticoagulation reversal agents are
expected to include questions regarding the appropriate
clinical setting for these agents. It is not anticipated that these
agents will be used to manage mild or moderate bleeding
events, which are usually well controlled by general sup-
portive measures. Most likely, the role of speciﬁc reversal
agents will be to help treat serious bleeding events in DOAC-
treated patients. At the present time, the approved indications
for idarucizumab are for cases of life-threatening or uncon-
trolled bleeding, or when patients require emergency surgery
or urgent procedures, each associated with a high risk of
bleeding.12 Ongoing clinical research should address unre-
solved issues, such as the optimal dose and duration for
andexanet alfa and ciraparantag in patients with bleeding
complications, as well as DOAC re-initiation strategies after
treatment with these reversal agents, particularly in patients
in whom emergent reversal of anticoagulation is required.
As clinical experience continues to evolve, the potential
role of prothrombin complex concentrates and other
nonspeciﬁc agents as supportive therapy in combination
with speciﬁc reversal agents will be better understood.20
In addition, the identiﬁcation of potential “go-to” local
experts (eg, hematologists, cardiologists, or pharmacists) at
each institution, who should be consulted in cases of severe
and uncontrolled bleeding, will be expected to improve
patient care and outcomes.
Finally, the relevant clinical societies may be asked to
support the widespread availability of these speciﬁc reversal
agents in all major and regional hospitals so that critical
cases may be treated as urgently as possible. For the smaller,
regional hospitals and rural healthcare facilities, ultimate
decisions to maintain stocks of these agents may depend on
local conditions. They will have to assess the costebeneﬁt
of relying on rapid transportation options or onsite avail-
ability of each agent as they become available.References
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